The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE Trial)

January 14, 2015

David Blitzer Docphin Ambassador

Name: David Blitzer, 2nd year Medical Student
Medical School: University of Pennsylvania
Undergrad: The College of William and Mary
Specialty Interest: Cardiology

Trial: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE Trial)

Journal: New England Journal of Medicine

Date: August 1, 2001


Given the burden of cardiovascular disease in the country, finding effective ways to treat individuals experiencing acute coronary syndromes and more importantly prevent more serious cardiovascular events such as myocardial infarction is critical. 

Key Takeaway:
What I find most intriguing about this trial is the immediacy with which the benefits of administering Clopidogrel with Aspirin were noted. Within 24 hours of initiation of treatment, the researchers noted a difference in cumulative hazard rates between subjects using Clopidogrel and those assigned to the placebo arm of the trial.

Potential Weaknesses:
While the rapidity of efficacy is one of the strengths of this trial, one of the weaknesses to consider would be that the length of follow-up, 12 months, was not sufficient to expose any long term benefits or consequences to Clopidogrel treatment.

The opinions expressed are the sole opinions of the author. If content is related to general and specific health issues, the information contained in the Site is made available with the express understanding that neither Docphin and/or the other authors on the Site, nor the Site itself, nor members of the Site are dispensing medical advice and do not intend any of this information to be used for self diagnosis or treatment. IF YOU HAVE ANY QUESTIONS OR CONCERNS ABOUT YOUR HEALTH AND BEFORE STARTING OR STOPPING ANY TREATMENT OR ACTING UPON INFORMATION CONTAINED ON THE SITE, YOU SHOULD CONTACT YOUR OWN PHYSICIAN OR HEALTH CARE PROVIDER.